Stocks · News reference
Niagen Bioscience Announces Selection Of Evotec As Contract Research Organization For IND-Enabling Studies Of NB4168 In Ataxia Telangiectasia
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 12:35 PM
- Checked
- Aug 3, 2026, 12:35 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Evotec Q2 EPS $(0.15) Misses $(0.06) Estimate, Sales $166.802M Miss $212.370M Estimate
Evotec (NASDAQ:EVO) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.06) by 150 percent. This is a 15.38 percent decrease over losses of $(0.14) per share from the same
Read original at benzingaEvotec Affirms FY2026 Sales Guidance of $667.470M-$714.310M vs $673.750M Est
Evotec (NASDAQ:EVO) affirms FY2026 sales outlook from $667.470 million-$714.310 million to $667.470 million-$714.310 million vs $673.750 million estimate.
Read original at benzingaOdyssey Taps Evotec's AI-Driven Discovery Platform To Advance Autoimmune, Inflammatory Disease Programs
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's
Read original at benzingaNiagen Bioscience Announces Online And Retail Availability Of Tru Niagen At GNC And Sam's Club Locations Across 44 States
Read original at benzingaNiagen Bioscience Announces Availability Of Its Healthy-Aging NAD+ Supplement Tru Niagen On Walmart.com
The launch expands access to Tru Niagen through one of the country’s largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven, science-backed NAD+ supplement to
Read original at benzinga